- Markets
- Healthcare
- ANUHPHR
ANUHPHR
New to Zerodha? Sign-up for free.
New to Zerodha? Sign-up for free.
-
Share Price
-
Financials
-
Revenue mix
-
Shareholdings
-
Peers
-
Forensics
- 5D
- 1M
- 6M
- YTD
- 1Y
- 5Y
- MAX
This data is currently unavailable for this company.
-
Summary
-
Profit & Loss
-
Balance sheet
-
Cashflow
This data is currently unavailable for this company.
(In Cr.) |
---|
(In Cr.) | ||||
---|---|---|---|---|
This data is currently unavailable for this company. |
(In %) |
---|
(In Cr.) |
---|
Financial Year (In Cr.) |
---|
-
Product wise
-
Location wise
Revenue Mix
This data is currently unavailable for this company.
Revenue Mix
This data is currently unavailable for this company.
Recent events
-
News
-
Corporate Actions
Anuh Pharma June-Quarter PAT 95.1 Million Rupees
Aug 9 (Reuters) - Anuh Pharma Ltd ANUH.BO:
ANUH PHARMA JUNE-QUARTER PAT 95.1 MILLION RUPEES
ANUH PHARMA JUNE-QUARTER REVENUE FROM OPERATIONS 1.38 BILLION RUPEES
Source text for Eikon: ID:nBSE82kZjz
Further company coverage: ANUH.BO
(([email protected];))
Aug 9 (Reuters) - Anuh Pharma Ltd ANUH.BO:
ANUH PHARMA JUNE-QUARTER PAT 95.1 MILLION RUPEES
ANUH PHARMA JUNE-QUARTER REVENUE FROM OPERATIONS 1.38 BILLION RUPEES
Source text for Eikon: ID:nBSE82kZjz
Further company coverage: ANUH.BO
(([email protected];))
Anuh Pharma Says Invests In Houban Energy 5 For Solar Project
April 4 (Reuters) - Anuh Pharma Ltd ANUH.BO:
INVESTMENT IN HOUBAN ENERGY 5 FOR SOLAR PROJECT
Source text for Eikon: ID:nBSE7MmGfl
Further company coverage: ANUH.BO
(([email protected];))
April 4 (Reuters) - Anuh Pharma Ltd ANUH.BO:
INVESTMENT IN HOUBAN ENERGY 5 FOR SOLAR PROJECT
Source text for Eikon: ID:nBSE7MmGfl
Further company coverage: ANUH.BO
(([email protected];))
Anuh Pharma Gets EDQM Approval For CEP Of Sulfadoxine API
Feb 28 (Reuters) - Anuh Pharma Ltd ANUH.BO:
APPROVAL FROM EDQM FOR CEP OF SULFADOXINE API WHICH IS AN ANTI-MALARIAL DRUG
Source text for Eikon: ID:nBSE75hVMs
Further company coverage: ANUH.BO
(([email protected];))
Feb 28 (Reuters) - Anuh Pharma Ltd ANUH.BO:
APPROVAL FROM EDQM FOR CEP OF SULFADOXINE API WHICH IS AN ANTI-MALARIAL DRUG
Source text for Eikon: ID:nBSE75hVMs
Further company coverage: ANUH.BO
(([email protected];))
Anuh Pharma Ltd Dec-Quarter Pat Rises
Feb 9 (Reuters) - Anuh Pharma Ltd ANUH.BO:
ANUH PHARMA LTD DEC-QUARTER PAT 191.1 MILLION RUPEES VERSUS 93.1 MILLION RUPEES
ANUH PHARMA LTD DEC-QUARTER REVENUE FROM OPERATIONS 1.72 BILLION RUPEES VERSUS 1.39 BILLION RUPEES
Source text for Eikon: ID:nBSE83lMqK
Further company coverage: ANUH.BO
(([email protected];))
Feb 9 (Reuters) - Anuh Pharma Ltd ANUH.BO:
ANUH PHARMA LTD DEC-QUARTER PAT 191.1 MILLION RUPEES VERSUS 93.1 MILLION RUPEES
ANUH PHARMA LTD DEC-QUARTER REVENUE FROM OPERATIONS 1.72 BILLION RUPEES VERSUS 1.39 BILLION RUPEES
Source text for Eikon: ID:nBSE83lMqK
Further company coverage: ANUH.BO
(([email protected];))
Anuh Pharma Got Approval From EDQM For CEP Of Gliclazide API
Aug 11 (Reuters) - Anuh Pharma Ltd ANUH.BO:
ECEIVED APPROVAL FROM EDQM FOR CEP OF GLICLAZIDE API
Source text for Eikon: ID:nBSE1RMk0L
Further company coverage: ANUH.BO
(([email protected];))
Aug 11 (Reuters) - Anuh Pharma Ltd ANUH.BO:
ECEIVED APPROVAL FROM EDQM FOR CEP OF GLICLAZIDE API
Source text for Eikon: ID:nBSE1RMk0L
Further company coverage: ANUH.BO
(([email protected];))
Anuh Pharma Received Approval From EDQM For CEP Of Azithromycin API
July 13 (Reuters) - Anuh Pharma Ltd ANUH.BO:
RECEIVED APPROVAL FROM EDQM FOR CEP OF AZITHROMYCIN API, A BROAD SPECTRUM MACROLIDE ANTIBIOTIC
Further company coverage: ANUH.BO
(([email protected];))
July 13 (Reuters) - Anuh Pharma Ltd ANUH.BO:
RECEIVED APPROVAL FROM EDQM FOR CEP OF AZITHROMYCIN API, A BROAD SPECTRUM MACROLIDE ANTIBIOTIC
Further company coverage: ANUH.BO
(([email protected];))
Events:
Dividend
Dividend
Dividend
Dividend
Bonus
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
Bonus
Dividend
Dividend
Dividend
Dividend
More Micro Cap Ideas
See similar 'Micro' cap companies with recent activity
Promoter Buying
Companies where the promoters are bullish
Capex
Companies investing on expansion
Superstar Investor
Companies where well known investors have invested
Popular questions
-
Business
-
Financials
-
Share Price
-
Shareholdings
What does Anuh Pharma do?
Anuh Pharma Ltd is a leading manufacturer of Active Pharmaceutical Ingredients (APIs) and also deals in bulk drugs, chemicals, and pharmaceutical formulations.
Who are the competitors of Anuh Pharma?
Anuh Pharma major competitors are Kwality Pharma, Wanbury, Shivalik Rasayan, Sakar Healthcare, Bharat Parenterals, Prevest Denpro, Medicamen Biotech. Market Cap of Anuh Pharma is ₹870 Crs. While the median market cap of its peers are ₹689 Crs.
Is Anuh Pharma financially stable compared to its competitors?
Anuh Pharma seems to be financially stable compared to its competitors. The probability of it going bankrupt or facing a financial crunch seem to be lower than its immediate competitors.
Does Anuh Pharma pay decent dividends?
The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. Anuh Pharma latest dividend payout ratio is 20.86% and 3yr average dividend payout ratio is 25.75%
How has Anuh Pharma allocated its funds?
Companies resources are majorly tied in miscellaneous assets
How strong is Anuh Pharma balance sheet?
Balance sheet of Anuh Pharma is strong. It shouldn't have solvency or liquidity issues.
Is the profitablity of Anuh Pharma improving?
The profit is oscillating. The profit of Anuh Pharma is ₹50.25 Crs for TTM, ₹60.06 Crs for Mar 2024 and ₹36.18 Crs for Mar 2023.
Is the debt of Anuh Pharma increasing or decreasing?
Yes, The debt of Anuh Pharma is increasing. Latest debt of Anuh Pharma is ₹8.1 Crs as of Sep-24. This is greater than Mar-24 when it was -₹17.32 Crs.
Is Anuh Pharma stock expensive?
Anuh Pharma is expensive when considering the EV/EBIDTA, however latest PE is < 3 yr avg PE. Latest PE of Anuh Pharma is 17.32, while 3 year average PE is 19.73. Also latest EV/EBITDA of Anuh Pharma is 14.29 while 3yr average is 13.74.
Has the share price of Anuh Pharma grown faster than its competition?
Anuh Pharma has given better returns compared to its competitors. Anuh Pharma has grown at ~20.17% over the last 3yrs while peers have grown at a median rate of 17.54%
Is the promoter bullish about Anuh Pharma?
Promoters stake in the company seems stable, and we need to go through filings and allocation of resources to gauge promoter bullishness. Latest quarter promoter holding in Anuh Pharma is 69.92% and last quarter promoter holding is 69.92%.
Are mutual funds buying/selling Anuh Pharma?
There is Insufficient data to gauge this.